BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Dec. 3, 2003
View Archived Issues
Maxim's Preclinical Cancer Work Nets Potential $27M Myriad Deal
Maxim Pharmaceuticals Inc. nailed down a potential $27 million licensing deal centered on its apoptosis-inducing cancer compounds with Myriad Genetics Inc. (BioWorld Today)
Read More
Stressgen, Roche Add New Indications To Collaboration
Read More
Europeans Continue Struggling To Blend The Colors Of Biotech
Read More
Incoming EU Members Want Their Piece Of The Biotech Pie
Read More
Sepracor's Inhaled Xopenex Positive In Phase III Studies
Read More
Other News To Note
Read More